CA2799391A1 - Improved process for a folate-targeted agent - Google Patents

Improved process for a folate-targeted agent Download PDF

Info

Publication number
CA2799391A1
CA2799391A1 CA2799391A CA2799391A CA2799391A1 CA 2799391 A1 CA2799391 A1 CA 2799391A1 CA 2799391 A CA2799391 A CA 2799391A CA 2799391 A CA2799391 A CA 2799391A CA 2799391 A1 CA2799391 A1 CA 2799391A1
Authority
CA
Canada
Prior art keywords
formula
compound
buffer
treating
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2799391A
Other languages
English (en)
French (fr)
Inventor
Daniel S. Reno
Katheryn Marie Stanford
Iontcho Radoslavov Vlahov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CA2799391A1 publication Critical patent/CA2799391A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2799391A 2010-05-19 2011-05-19 Improved process for a folate-targeted agent Abandoned CA2799391A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34644410P 2010-05-19 2010-05-19
US61/346,444 2010-05-19
US35102210P 2010-06-03 2010-06-03
US61/351,022 2010-06-03
PCT/US2011/037134 WO2011146707A1 (en) 2010-05-19 2011-05-19 Improved process for a folate-targeted agent

Publications (1)

Publication Number Publication Date
CA2799391A1 true CA2799391A1 (en) 2011-12-04

Family

ID=44992057

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2799391A Abandoned CA2799391A1 (en) 2010-05-19 2011-05-19 Improved process for a folate-targeted agent

Country Status (11)

Country Link
US (2) US20130065841A1 (https=)
JP (1) JP2013526577A (https=)
KR (1) KR20130079431A (https=)
CN (1) CN102984943B (https=)
BR (1) BR112012029458A2 (https=)
CA (1) CA2799391A1 (https=)
IL (1) IL222964A0 (https=)
MX (1) MX2012013250A (https=)
RU (1) RU2012154914A (https=)
SG (1) SG185592A1 (https=)
WO (1) WO2011146707A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6676650B2 (ja) 2015-03-13 2020-04-08 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 疾患を処置するためのコンジュゲート
US20200323991A1 (en) * 2016-03-29 2020-10-15 Endocyte, Inc. Pbd conjugates for treating diseases
WO2019196999A1 (en) 2018-04-11 2019-10-17 Radisurf Aps Compositions for forming polymer brushes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100381177C (zh) * 2003-01-27 2008-04-16 恩多塞特公司 维生素受体结合递药缀合物
CN100423778C (zh) * 2003-11-25 2008-10-08 上海复旦张江生物医药股份有限公司 用于上载抗肿瘤药物的脂质体载体及其制备方法和应用
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives

Also Published As

Publication number Publication date
CN102984943B (zh) 2016-01-13
US20130065841A1 (en) 2013-03-14
WO2011146707A1 (en) 2011-11-24
SG185592A1 (en) 2012-12-28
KR20130079431A (ko) 2013-07-10
IL222964A0 (en) 2013-02-03
MX2012013250A (es) 2013-03-05
JP2013526577A (ja) 2013-06-24
US20140066593A1 (en) 2014-03-06
CN102984943A (zh) 2013-03-20
RU2012154914A (ru) 2014-06-27
BR112012029458A2 (pt) 2015-10-20

Similar Documents

Publication Publication Date Title
EP3735987A1 (en) Amanitin antibody conjugate
CN109316605A (zh) 叶酸受体结合配体-药物偶联物
CA2799391A1 (en) Improved process for a folate-targeted agent
CN116635408A (zh) 反应性偶联物
EP4417618A1 (en) Epha2 bicyclic peptide ligand and conjugate thereof
EP3738608A1 (en) Non-natural amatoxin-type antibody conjugate
CN111205350A (zh) 作为组蛋白脱乙酰酶抑制剂的大环硫代酸酯前体药物
EP2571362A1 (en) Improved process for a folate-targeted agent
EP4201429A1 (en) Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor
EP4134157A1 (en) Use of ligand linker substrate for purification
EP3950700A1 (en) Peptide complex and production method therefor, and use of said peptide complex
EP4612144A1 (en) Carbonic anhydrase ix ligands for targeted delivery applications
RU2798981C2 (ru) Конъюгат антитела с аматоксином неприродного типа
EP4365184A1 (en) Analysis method for peptide bound to carrier for liquid phase peptide synthesis
RU2840926C2 (ru) Конъюгат антитела с аматоксином неприродного типа
Baudat et al. Cyanine 5-huwentoxin-IV as a novel imaging probe to detect hNav1. 7 channel overexpressed in non-small cell lung cancer
EP4353248A1 (en) Calcium-sensing receptor agonist composition and application thereof
KR102949474B1 (ko) 뉴클레오린에 특이적으로 결합하는 agm 펩타이드를 제조하는 방법
RU2809116C2 (ru) Конъюгат амантина с антителом
HK40035181A (en) Amanitin antibody conjugate
EP3604386B1 (en) Degradable polyethylene glycol derivative having disulfide linker
CN120530091A (zh) 抗体药物复合物用连接子和抗体药物复合物
Noreen et al. Development of novel derivatives of pegylated doxorubicin: new anticancer drug delivery system
WO2025207387A1 (en) Synthesis of membrane permeable macrocyclic peptides via imidazopyridinium grafting
CN106380508A (zh) 一种抗体偶联药物连接子的工业化生产方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160519